Periodic Reporting for period 2 - ULTRHAS (ULtrafine particles from TRansportation – Health Assessment of Sources)
Reporting period: 2023-03-01 to 2024-08-31
The ULTRHAS project addresses the human health impact of ultrafine particles (UFPs, particles < 100nm) from emissions of different transport modes. The project applies cutting-edge exhaust generation and exposure approaches and explores the importance of physicochemical characteristics and atmospheric processes for biological effects of UFPs. The overarching objective is to improve risk assessment of air pollutants and to advice policymakers and regulators on more targeted mitigation measures against the emission components and sources that contribute the most to adverse effects in the population. This will allow for more efficient initiatives to improve urban air quality and promote health and well-being.
During the first project period (months 1-18) the necessary administrative systems and operating bodies were established, along with tools for internal and external communication and dissemination. Exposure systems and cell models were optimized, standard operating procedures (SOPs) developed to align test systems across partner labs, as well as tools for health impact assessment. In a pilot-campaign performed in collaboration with another ongoing project, fresh and aged emissions from light-duty vehicles were tested in different lung cell models, providing valuable input for the main ULTRHAS test campaigns. Studies were also performed with model UFPs (from a soot generator) varying content of semi-volatile organic chemicals (SVOCs) to further explore the importance of particle composition. At the end of the first reporting period, the first major ULTRHAS test campaign on aircraft (JP-8 feul) and ship emissions from Heavy Fuel Oil (HFO) and low-sulfur marine Gas Oil (MGO) was successfully performed, and results were analyzed into the next period.
In the second project period (months 19-36), the project performed two more large test campaigns: non-exhaust emission testing at the Bundeswehr University (UniBW) and the Helmholtz Center in Munich, and light duty/passenger car emission testing at the University of Eastern Finland, in Kuopio. In the non-exhaust emission campaign, break emissions were tested from non-asbestos organic (NAO) brake pads and low metallic (LM) brake pads, on a novel Euro 7 compatible brake dyno developed at UniBW. Furthermore, a spark discharge aerosol generator producing copper-rich UFPs was used to simulate rail catenary sparking. In the light-duty vehicle campaign fresh and aged emissions were produced from Euro 6d gasoline, diesel, and natural gas engines. The emissions from all test campaigns, comprehensively characterized for physical and chemical properties, and 3D lung tissue models have been exposed at Air-Liquid Interface (ALI). In vitro tissue/cell models of brain, blood, liver, and intestine are now exposed to conditioned medium sampled from the basolateral compartment of the ALI-exposed lung tissue model, to simulate and explore potential effects on organs beyond the lung.
Mechanistic studies are ongoing to further explore the link between particle composition and biological effects, focusing in particular on the role of soluble chemical or the so-called Trojan Horse effect. Combustion particle properties have been manipulated by denuding CAST aerosols to remove SVOCs, by extracting soluble organic chemicals, and by coating pure carbon black nanoparticles with different polycyclic aromatic hydrocarbons (PAHs). The role of different chemical groups from combustion UFPs has ben further studied by exposing cells to different fractionation of soluble organic chemicals (polar to nonpolar groups) and studying effects of individual chemicals present on the particles. Translocation of particles and soluble chemicals across an in vitro model of the blood-air barrier is also investigated.
In the second project period (months 19-36), the project performed two more large test campaigns: non-exhaust emission testing at the Bundeswehr University (UniBW) and the Helmholtz Center in Munich, and light duty/passenger car emission testing at the University of Eastern Finland, in Kuopio. In the non-exhaust emission campaign, break emissions were tested from non-asbestos organic (NAO) brake pads and low metallic (LM) brake pads, on a novel Euro 7 compatible brake dyno developed at UniBW. Furthermore, a spark discharge aerosol generator producing copper-rich UFPs was used to simulate rail catenary sparking. In the light-duty vehicle campaign fresh and aged emissions were produced from Euro 6d gasoline, diesel, and natural gas engines. The emissions from all test campaigns, comprehensively characterized for physical and chemical properties, and 3D lung tissue models have been exposed at Air-Liquid Interface (ALI). In vitro tissue/cell models of brain, blood, liver, and intestine are now exposed to conditioned medium sampled from the basolateral compartment of the ALI-exposed lung tissue model, to simulate and explore potential effects on organs beyond the lung.
Mechanistic studies are ongoing to further explore the link between particle composition and biological effects, focusing in particular on the role of soluble chemical or the so-called Trojan Horse effect. Combustion particle properties have been manipulated by denuding CAST aerosols to remove SVOCs, by extracting soluble organic chemicals, and by coating pure carbon black nanoparticles with different polycyclic aromatic hydrocarbons (PAHs). The role of different chemical groups from combustion UFPs has ben further studied by exposing cells to different fractionation of soluble organic chemicals (polar to nonpolar groups) and studying effects of individual chemicals present on the particles. Translocation of particles and soluble chemicals across an in vitro model of the blood-air barrier is also investigated.
The ULTRHAS project is progressing according to schedule on developing its in vitro approach, combining ALI-exposure of cutting-edge 3D lung models with indirect exposure of 2D and 3D secondary tissue models to fully characterised exhausts from different sources. The approach will allow for simultaneous assessment of lung and secondary tissue effects of airborne pollutants from the same ALI-exposure. Furthermore, the DALY-intake model is being modified for assessment of UFP exposure based on in vitro data. If successful, this will considerably advance toxicity testing and health impact assessment of inhaled pollutants beyond current state of the art.
The ULTRHAS project is expected to provide novel insight into the mechanisms and key drivers of adverse effects from transport emissions, evaluating the role of UFPs, particle number concentrations, chemical composition as well as specific emission sources, and expedite the progress towards solutions to urban air pollution, which is currently the largest environmental health problem, in Europe and worldwide.
Developing cost-efficient solutions to reduce the adverse health impact from transport emissions is of considerable significance for European and global economy. The global demand for cleaner, low-emission transport technologies also provides a market for new and innovative solutions. Thus, ULTRHAS will provide an attractive knowledge base for the commercial development of improved engine and exhaust cleansing technologies, novel fuel types and improved wear components.
By providing solutions and tools for local authorities and policy makers to assess and prevent health impacts of transport mode emissions, and by addressing societal needs and economic consequences, also for the individual, ULTRHAS will provide means to raise public awareness and increase acceptance of the mitigation measures needed to improve urban air quality, public health and well-being.
The ULTRHAS project is expected to provide novel insight into the mechanisms and key drivers of adverse effects from transport emissions, evaluating the role of UFPs, particle number concentrations, chemical composition as well as specific emission sources, and expedite the progress towards solutions to urban air pollution, which is currently the largest environmental health problem, in Europe and worldwide.
Developing cost-efficient solutions to reduce the adverse health impact from transport emissions is of considerable significance for European and global economy. The global demand for cleaner, low-emission transport technologies also provides a market for new and innovative solutions. Thus, ULTRHAS will provide an attractive knowledge base for the commercial development of improved engine and exhaust cleansing technologies, novel fuel types and improved wear components.
By providing solutions and tools for local authorities and policy makers to assess and prevent health impacts of transport mode emissions, and by addressing societal needs and economic consequences, also for the individual, ULTRHAS will provide means to raise public awareness and increase acceptance of the mitigation measures needed to improve urban air quality, public health and well-being.